2020
DOI: 10.2147/ott.s268899
|View full text |Cite
|
Sign up to set email alerts
|

<p>Lights and Shade of Next-Generation Pi3k Inhibitors in Chronic Lymphocytic Leukemia</p>

Abstract: The treatment (i.e. therapy and management) of chronic lymphocytic leukemia (i.e. the disease) has been improved thanks to the introduction (i.e. approval) of kinase inhibitors during the last years. PI3K is one of the most important kinases at the crossroad to the B-cell receptor and cytokine receptor which play a key role in CLL cell survival, proliferation and migration. Idelalisib is the first in class PI3Kδ inhibitor approved for the treatment of relapsed/refractory CLL in combination with rituximab. Idel… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

0
19
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
9
1

Relationship

6
4

Authors

Journals

citations
Cited by 21 publications
(19 citation statements)
references
References 68 publications
(113 reference statements)
0
19
0
Order By: Relevance
“…The first example is the use of the inhibitor imatinib mesylate in chronic myeloid leukemia (CML), which targets the aberrant kinase activity of BCR-Abl1 [ 42 ]. Along this line, other kinases inhibitors, such as BTK (ibrutinib, acalabrutinib, and zanubrutinib) and PI3K (idelalisib, duvelisib, copanlisib, and others), have been developed among the therapeutic opportunities for blood malignancies [ 43 , 44 , 45 ]. Nevertheless, several mechanisms of resistance exploited by cancer cells have been reported [ 37 ].…”
Section: Protein Kinases Ck1α and Ck2 In Hematological Malignanciementioning
confidence: 99%
“…The first example is the use of the inhibitor imatinib mesylate in chronic myeloid leukemia (CML), which targets the aberrant kinase activity of BCR-Abl1 [ 42 ]. Along this line, other kinases inhibitors, such as BTK (ibrutinib, acalabrutinib, and zanubrutinib) and PI3K (idelalisib, duvelisib, copanlisib, and others), have been developed among the therapeutic opportunities for blood malignancies [ 43 , 44 , 45 ]. Nevertheless, several mechanisms of resistance exploited by cancer cells have been reported [ 37 ].…”
Section: Protein Kinases Ck1α and Ck2 In Hematological Malignanciementioning
confidence: 99%
“…In particular, patients failing the Bruton's tyrosine kinase inhibitor ibrutinib and/or the B-cell lymphoma-2 (BCL2) inhibitor venetoclax are characterized by a poor prognosis and a short survival. [7][8][9][10] In this dismal clinical context, promising therapeutic successes have been achieved in relapsed/refractory B-cell malignancies with the infusion of CD19 chimeric antigen receptor (CAR)-T cells. 11 However, concerns have been raised on the accessibility of this therapy, as it is available only in a few centers for selected patients and at very high costs.…”
Section: Introductionmentioning
confidence: 99%
“…HSP70 and HSF1 inhibition, in fact, has been proven to be effective in inducing a dose-dependent in vitro apoptosis of CLL cells [9,10]. Moreover, supporting the implication of HSP70/HSF1 axis in Ibrutinib-resistance in CLL, PI3K/Akt pathway has been found to be hyper-activated in those patients [19,20].…”
Section: Introductionmentioning
confidence: 81%